Skip to main content
SpringerLink
Log in

Authors’ Reply to Robert P. Giugliano and Colleagues’ Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”

  • Letter to the Editor
  • Published:
Drug Safety Aims and scope Submit manuscript

The Original Article was published on 24 February 2021

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Giugliano RP, De Caterina R, Yamashita T. Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”. Drug Saf. 2021. https://doi.org/10.1007/s40264-021-01055-1

  2. Raschi E, Fusaroli M, Diemberger I, Poluzzi E. Direct oral anticoagulants and interstitial lung disease: emerging clues from pharmacovigilance. Drug Saf. 2020;43(11):1191–4.

    Article  Google Scholar 

  3. Raschi E, Poluzzi E, Salvo F, et al. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutr Metab Cardiovasc Dis. 2018;28(6):533–42.

    Article  CAS  Google Scholar 

  4. Wakao R, Taavola H, Sandberg L, et al. Data-driven identification of adverse event reporting patterns for Japan in VigiBase, the WHO global database of individual case safety reports. Drug Saf. 2019;42(12):1487–98.

    Article  CAS  Google Scholar 

  5. Iwasa E, Fujiyoshi Y, Kubota Y, et al. Interstitial lung disease as an adverse drug reaction in Japan: exploration of regulatory actions as a basis for high reporting. Drug Saf. 2020;43(11):1121–31.

    Article  Google Scholar 

  6. Sandberg L, Taavola H, Aoki Y, Chandler R, Norén GN. Risk factor considerations in statistical signal detection: using subgroup disproportionality to uncover risk groups for adverse drug reactions in VigiBase. Drug Saf. 2020;43(10):999–1009.

    Article  Google Scholar 

  7. Wisniewski AF, Bate A, Bousquet C, et al. Good signal detection practices: evidence from IMI PROTECT. Drug Saf. 2016;39(6):469–90.

    Article  Google Scholar 

  8. Torp-Pedersen C, Goette A, Nielsen PB, et al. ‘Real-world’ observational studies in arrhythmia research: data sources, methodology, and interpretation A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). Europace. 2020; 22(5):831–32

    Article  Google Scholar 

  9. Matsuno O. Drug-induced interstitial lung disease: mechanisms and best diagnostic approaches. Respir Res. 2012;13(1):39. https://doi.org/10.1186/1465-9921-13-39.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Gatti M, Raschi E, Poluzzi E, et al. The complex management of atrial fibrillation and cancer in the COVID-19 era: drug interactions, thromboembolic risk, and proarrhythmia. Curr Heart Fail Rep. 2020;17(6):365–83.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacology Unit, Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Via Irnerio 48, 40126, Bologna, Italy

    Emanuel Raschi, Michele Fusaroli & Elisabetta Poluzzi

  2. Cardiology Unit, Department of Experimental, Diagnostic and Specialty Medicine, Alma Mater Studiorum, University of Bologna, Bologna, Italy

    Igor Diemberger

Authors
  1. Emanuel Raschi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michele Fusaroli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Igor Diemberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elisabetta Poluzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emanuel Raschi.

Ethics declarations

Funding

Emanuel Raschi, Igor Diemberger, and Elisabetta Poluzzi are supported by institutional research funds (Ricerca Fondamentale Orientata). The letter was not funded in whole or in part by any research grant or funding body.

Conflict of interests/Competing interests

Igor Diemberger reports minor speaker fees from Bayer, Boehringer Ingelheim, Daiichi Sankyo, and Pfizer, outside the submitted work. Emanuel Raschi, Michele Fusaroli, and Elisabetta Poluzzi have no conflicts of interest that are directly relevant to the content of this letter.

Ethics approval

Not applicable.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and material

Data supporting the findings of this study were derived from the following resource, available in the public domain: https://www.fis.fda.gov/exten sions/FPD-QDE-FAERS /FPD-QDE-FAERS.html.

Code availability

Codes for the analyses can be made available by the authors upon reasonable request.

Authors’ contributions

All authors assisted with the preparation of the letter and read and approved the final version.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Raschi, E., Fusaroli, M., Diemberger, I. et al. Authors’ Reply to Robert P. Giugliano and Colleagues’ Comment on: “Direct Oral Anticoagulants and Interstitial Lung Disease: Emerging Clues from Pharmacovigilance”. Drug Saf 44, 505–506 (2021). https://doi.org/10.1007/s40264-021-01054-2

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-021-01054-2

Search

Navigation